Disability

Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease Analysis

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed…

1 year ago

BioNTX Names Osteal Therapeutics 2023 Rising Star

President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award…

1 year ago

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as…

1 year ago

NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders

CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…

1 year ago

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed…

1 year ago

Osteal Therapeutics Closes $23M Series C Financing

Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM…

1 year ago

NeurAxis Reports Second Quarter 2023 Financial Results

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company…

1 year ago

IntelGenx Provides RIZAFILM® U.S. Commercialization Update

Receives first purchase order from Gensco® PharmaSAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company"…

1 year ago

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Highlights AHI signs a letter of Intent with Unisure.SCOR (SCR.FP) and Unisure to collaborate with AHI.SCOR is one of the…

1 year ago

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

1 year ago